Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2019-03-22 | Mr. Tanda became President and Chief Executive Officer of Aptar on February 1, 2017. Prior to this, Mr. Tanda served from 2007 until 2017 as an Executive Managing Board Director at Royal DSM NV (leading global supplier of ingredients and material solutions for the food, dietary supplement, personal care, medical device, automotive, paint, electronic and bio-material markets), where he was responsible for DSM's Nutrition and Pharma activities, as well as DSM's presence in the Americas and various corporate duties. Mr. Tanda was a director of Patheon NV (formerly a NYSE-listed company that provided pharmaceutical development and manufacturing services) from March 2016 until the company was sold to Thermo Fisher Scientific in August 2017. The Board of Directors concluded that Mr. Tanda should continue to serve as a director of Aptar due in part to his role as President and Chief Executive Officer, his extensive global experience leading and building successful business-to-business organizations in several markets currently served by Aptar, as well as his transaction and integration experience. |
| 2021-03-26 | Mr. Tanda became President and CEO of Aptar on February 1, 2017. 2020 Summary Compensation Table shows total compensation of $7,018,822. |
| 2022-03-25 | STEPHAN B. TANDA Executive Director Age: 56 Director since: 2017 President and CEO of AptarGroup, Inc. 2021 Summary Compensation Table Stephan B. Tanda 2021 Total Compensation $9,379,483 |
| 2023-03-24 | Mr. Tanda became President and Chief Executive Officer of Aptar in February 2017. ... Mr. Tanda does not receive additional compensation for his service as a director of Aptar. |
| 2024-03-22 | Mr. Tanda became President and Chief Executive Officer of Aptar in February 2017. Prior to this, Mr. Tanda served from 2007 to 2017 as an Executive Managing Board Director at Royal DSM NV (leading global supplier of ingredients and material solutions for the food, dietary supplement, personal care, medical device, automotive, paint, electronic and bio-material markets), where he was responsible for DSM’s Nutrition and Pharma activities, as well as DSM’s presence in the Americas and various corporate duties. Mr. Tanda is a director of Ingredion Incorporated (a NYSE-listed global supplier of high-quality food and industrial ingredient solutions). Mr. Tanda was a director of Patheon NV (formerly a NYSE-listed company that provided pharmaceutical development and manufacturing services) from March 2016 until the company was sold to Thermo Fisher Scientific in August 2017. Committees: None. 2023 Director Compensation: None (CEO does not receive additional compensation for board service). |
| 2025-03-28 | STEPHAN B. TANDA President & CEO, Aptar Age: 59 Director since: 2017 Committees: None ... Mr. Tanda, our Chief Executive Officer, does not receive additional compensation for his service as a director of Aptar. |
Data sourced from SEC filings. Last updated: 2026-02-03